All in a muddle
Article Abstract:
Prana Biotechnology the Alzheimer's Disease research company had informed the Australian Stock Exchange that further development of the drug Clioquinol is not warranted due to risk of side effects. This has come as a huge blow to the company's investors, scientists and management.
Publisher: B R W Media
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
Product development, Drugs, Alzheimer Disease Controllers, Biotechnology industry, Biotechnology industries, Alzheimer's disease, Anti-Alzheimer's disease agents, Prana Biotechnology Ltd., Clioquinol (Medication)
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Generic drug frenzy
Article Abstract:
The reasons behind the growth of competition in Australian generic drug business are examined.
Publisher: B R W Media
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
Forecasts, trends, outlooks, Marketing procedures, Research Findings, Generic Drugs, Pharmaceutical industry, Marketing research, Industry forecasts, Market research
Publication Name: Business Review Weekly
Subject: Business, general
ISSN: 0727-758X
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: Australia
Similar abstracts:
- Abstracts: Protel races on to a wider circuit. Drug frenzy. Dollar prophets
- Abstracts: AGL tries a new bulb. Primed for profit. Foodland falters
- Abstracts: Bulls are back. Green light for bulls. Bulls take charge
- Abstracts: Wall Street cracks. American influence. Stay in the comfort zonec
- Abstracts: A Bollinger bubble? Moving up. Easy does it
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.